The Castrate Resistant Prostate Cancer market is estimated to be valued at US$ 11.12 Bn in 2023 and is expected to exhibit a CAGR of 8.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Castrate resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that does not respond to hormone therapy. The market comprises of therapies targeting different mechanisms ... Read more

Castrate resistant prostate cancer (CRPC) refers to prostate cancer that continues to grow and spread even after the medical or surgical treatment to lower testosterone. It becomes resistant to these standard hormonal treatments that aimed to deprive prostate cancer cells of the male sex hormone testosterone that fuels their growth. Currently, chemotherapy is the standard treatment for CRPC, however improvements in diagnostics have led to earlier detection enabling new drug therapies which ... Read more